COST-EFFECTIVENESS ANALYSIS OF DIALYSIS AND KIDNEY TRANSPLANTATION TREATMENT IN TURKEY

Year 2015, Volume: 1 Issue: 13, 182 - 205, 11.01.2016

Vahit Yiğit , Ramazan Erdem

Abstract

The purpose of this study is to confirm the cost effectiveness of hemodialysis (HD), peritoneal dialysis (PD) and kidney transplantation (Tx) which are used for renal failure treatment with perspective of Social Security Instution (SSI) as well as confirm the alternative treatment methods’ amount consumed in budget. This research was conducted in 2013 at Akdeniz University Hospital. These treatment methods’ cost, life year and quality adjusted life year (QALY) were calculated by using Markov model and results were reduced by 3%. One-way sensitivity analysis was made for evaluating the effect of discount rate and study’s time period. Finally, to determine how the resource consumption of these treatments for budget impact analysis was conducted. In this study confirmed that a patient’s cost of HD is 29.592 TL, cost of PD is 29.061 TL, cost of Tx is 51.279 TL in first year of transplantation and 8.654 TL in second and the other years. Alternative treatment methods’ effectiveness values were evaluated with EQ-5D-5L scale. HD effectiveness value was confirmed as 0.6832, PD value was confirmed as 0.7092 and Tx value was confirmed as 0.8929. According to the markov model’s results, cost per patient of HD is 305.591 TL cost of PD is 322.895-TL and cost of Tx is 217.259 TL. HD QALY value is 6.63, PD QALY value is 8.02 and Tx QALY value is 13.00. According to markov model results; in one-year lifetime cost of HD was found as 36.892 TL/YL, cost of PD was found as 29.921 TL/YL and cost of kidney transplantation was found as 14.401 TL/YL. Meanwhile per QALY cost of HD was found as 46.105 TL/QALY, cost of PD was found as 40.274 TL/QALY and cost of Tx was found as 16.714 TL/QALY. According to cost-effectiveness analysis result when Tx was compared with HD, Tx provides incremental cost as 6.37 QALY and (-) 88.332,44 TL. Incremental Cost-Effectiveness Ratio (ICER) of Tx was calculated as (-) 13.865 TL per acquired QALY. When Tx was compared with PD, Tx provides incremental cost as 4.98 QALY and (-) 105.637 TL. ICER of Tx was calculated as (-) 21.207 TL per acquired QALY. Because of ICER is below the threshold in cost-effectiveness analysis, Tx is cost-effective both regarding to HD and PD. These three treatment methods’ financial charge is 2.047.633.644 TL in annual budget (2012) in Turkey. 4.64 % of SSI total health expenditure is estimated to be spent on HD, PD and Tx treatment.  

Keywords

Cost-Effectiveness Analysis, Hemodialysis, Peritoneal Dialysis, Kidney Transplantation

TÜRKİYE'DE DİYALİZ VE BÖBREK TRANSPLANTASYONU TEDAVİSİNİN MALİYET ETKİLİLİK ANALİZİ

Abstract

Bu araştırmanın amacı, son dönem böbrek yetmezliği tedavisinde uygulanan hemodiyaliz (HD), periton diyalizi (PD) ve böbrek transplantasyonu (Tx) tedavi yöntemlerinin Sosyal Güvenlik Kurumu (SGK) perspektifinden maliyet etkililiğini ve bu yöntemlerin bütçeden ne kadar kaynak tükettiğini tespit etmektir.. Araştırmada Markov modeli kullanılarak bu tedavi yöntemlerinin maliyeti, yaşam yılı ve kaliteye ayarlanmış yaşam yılı hesaplanmış ve hesaplanan sonuçlara %3 indirgeme yapılmıştır. Çalışmanın kapsadığı zaman dilimi ve iskonto oranının sonuçlara etkisini değerlendirmek için tek yönlü duyarlılık analizi yapılmıştır. Son olarak bu tedavilerin ne kadar kaynak tüketimini tespit etmek için bütçe etki analizi yapılmıştır. Araştırma sonuçlarına göre Markov modelinde belirlenen zaman diliminde hasta başına maliyet HD, PD ve Tx sırasıyla; 305.591-TL, 322.895-TL ve 217.259-TL; QALY değerleri ise HD 6.63, PD 8.02, Tx ise 12.99 olarak saptanmıştır. Araştırmada Markov modelinden elde edilen sonuçlara göre bir yıllık yaşam süresinde HD 36.892 TL/YL, PD 29.921 TL/YL ve Tx 14.401 TL/YL maliyet tespit edilirken QALY başına maliyet ise HD 46.105 TL/QALY, PD 40.274 TL/QALY ve Tx 16.714 TL/QALY olarak hesaplanmıştır. Maliyet etkililik analizi sonucuna göre Tx ile HD karşılaştırıldığında 6.37 QALY ve (-) 88.332 TL ilave maliyet sağlamaktadır. Maliyet etkililik analizinde ICER’ın eşik değerin çok altında olması nedeni ile Tx hem HD, hem de PD göre maliyet etkili olarak bulunmuştur. Markov modelinden elde edilen verilere göre SGK toplam sağlık harcamalarının ise %4.64’ünün RRT yöntemlerine harcandığı tahmin edilmektedir.

Keywords

maliyet etkililik analizi, hemodiyaliz, periton diyalizi, böbrek transplantasyonu

References

• Abu-Aisha, H.,Elamin, S. (2010). Peritoneal dialysis in Africa. Peritoneal Dialysis International, No.30, (23– 28).
• Briggs, A. Sculpher, M. (1998). An Introduction to Markov Modelling for Economic Evaluation, PharmacoEconomics, Vol.4, No. 13, (397–409).
• Cleemput, I., Kesteloot, K., Vanrenterghem, Y., & De Geest, S. (2004). “The Economic İmplications Of Non- Adherence After Renal Transplantation”, Pharmacoeconomics, Vol.18, No.22, (1217–34).
• Çalışkan, Z. (2009). Sağlık Hizmetlerinde Önceliklerin. Belirlenmesinde Ekonomik Değerlendirme Yöntemi Olarak Maliyet-Etkililik Analizi, Süleyman Demirel Üniversitesi İktisadi Ve İdari Bilimler Fakültesi Dergisi, Sayı.14, (311–332).
• Doğukan, A., Tokgöz, B., Oymak, O., Taşkapan, H., Sözüer, E., Yılmaz, Z.,Utaş, C. (2003). Böbrek Transplantasyonu Uygulanan Olgular: 5 Yıllık Sonuçların Analizi, Erciyes Tıp Dergisi, Cilt.2, Sayı.25, 86–91.
• Drummond, M. F., Schwartz, J. S., Jönsson, B., Luce, B. R., Neumann, P. J., Siebert, U., Sullivan, S. D. (2008). Key Principles For The İmproved Conduct Of Health Technology Assessments For Resource Allocation Decisions, International Journal Of Technology Assessment In Health Care, Vol.3, No.24, (244–58;362– 8).
• Drummond, M. F., Sculpher, M. J., Torrance, G. W., O’Brien, B. J., & Stoddart, G. L. (2005). Methods For The Economic Evaluation Of Health Care Programmes (Third Edit.). United States: Oxford University Press.
• El Nahas, A. M.,& Bello, A. K. (2005). Chronic kidney disease: the global challenge, The Lancet, No.365(9456), 331–340.
• Elsharif, M., Elsharif, E., & Gadour, W. (2010). Costs Of Hemodialysis And Kidney Transplantation In Sudan: A Single Center Experiences, Iranian Journal Of Kidney, http://europepmc.org/abstract/med/20852367 (01.05.2013).
• Erek, E., Sever, M. Ü., Akoglu, E., Sarıyar, M., & Al., E. (2004). Cost Of Renal Replacement Therapy In Turkey, 9(Septembe), (33–38).
• Ersoy, F. F. (2005). Son Dönem Böbrek Yetmezliğinde Uygun Diyaliz Yönteminin Seçimi, Turkiye Klinikleri Journal of Internal Medical Sciences, Cilt.1, Sayı.21, (88–92).
• EuroQol. (2013). EQ-5D-5L Ölçeği. http://www.euroqol.org/home.html(12.05.2013).
• Euroqol - A New Facility For The Measurement Of Health-Related Quality Of Life. (1990). Health Policy, Vol.3, No.16, (199–208).
• Evans, R. W.,& Kitzmann, D. J. (1998). An Economic Analysis Of Kidney Transplantation. Surgical Clinics Of North America, Vol.1, No.78, (149–174).
• FoxJuila, R.,& Dogan, F. (2005). Introduction To Markov Modeling. Içinde J. Fox-Rushby & J. Cairns (Ed.), Economic Evaluation (51–64). Open University Press.
• Fresenius Medical Care. (2012). ESRD Patients in 2012: A Global Perspective. http://www.vision- fmc.com/files/pdf_2/ESRD_Patients_2012.pdf (11.05.2013).
• Fresenıus Medical Care. (2011). ESRD Patients in 2011: A Global Perspective. http://www.vision- fmc.com/files/download/ESRD/ESRD_Patients_in_2011.pdf, (11.05.2013).
• Hariharan, S., Johnson, C. P., Bresnahan, B. A., Taranto, S. E., McIntosh, M. J., & Stablein, D. (2000). Improved graft survival after renal transplantation in the United States, 1988 to 1996, The New England Journal Of Medicine, Vol.9, No.342, (605–12).
• Gafni A. Birch S. (2006), Incremental Cost-effectiveness ratios (ICERs): The Silence of the Lambda, Social Science and Medicine, No.62, (2091-2100).
• Jassal, S. V., Krahn, M. D., Naglıe, G., Zaltzman, J. S., Roscoe, J. M., Cole, E. H., & Redelmeıer, D. A. (2003). Kidney Transplantation in the Elderly: A Decision Analysis, Journal of the American Society of Nephrology, Vol.1, No.14, (187–196).
• Just, P. M., de Charro, F. T., Tschosik, E. A., Noe, L. L., Bhattacharyya, S. K., & Riella, M. C. (2008). Reimbursement And Economic Factors Influencing Dialysis Modality Choice Around The World, Nephrology, Dialysis, Transplantation  : Official Publication Of The European Dialysis And Transplant Association, European Renal Association, Vol.7, No.23, (2365–73).
• Just, P. M., Riella, M. C., Tschosik, E. A., Noe, L. L., Bhattacharyya, S. K., & de Charro, F. (2008a). Economic Evaluations Of Dialysis Treatment Modalities, Health Policy (Amsterdam, Netherlands), Vol.2-3, No.86, (163–80).
• Just, P. M., Riella, M. C., Tschosik, E. A., Noe, L. L., Bhattacharyya, S. K., & de Charro, F. (2008b). Economic Evaluations Of Dialysis Treatment Modalities, Health Policy (Amsterdam, Netherlands), Vol.2-3, No.86, (163–80).
• Karopadi, A.,Mason, G. (2013). Cost Of Peritoneal Dialysis And Haemodialysis Across The World. Nephrol Dial Transplant, No.28, (2553–2569).
• Kernick D. McDonald R. (2002), Getting Health Economics into Practise, Edited by David Kernick, Radclife Medical Press, United Kingdom.
• Kerr, M., Bray, B., Medcalf, J., O’Donoghue, D. J., & Matthews, B. (2012). Estimating The Financial Cost Of Chronic Kidney Disease To The NHS İn England, Nephrology Dialysis Transplantation, 27(August), 1– 8.
• Kirby, L.,Vale, L. (2001). Dialysis For End-Stage Renal Disease. International Journal Of Technology Assessment In Health Care, Vol.2, No.17, (181–189).
• Kontodimopoulos, N.,& Niakas, D. (2008). An Estimate Of Lifelong Costs And Qalys In Renal Replacement Therapy Based On Patients’ Life Expectancy, Health Policy (Amsterdam, Netherlands), Vol.1, No.86, (85–96).
• Lee, A. J., Morgan, C. L., Conway, P., & Currie, C. J. (2005). Characterisation And Comparison Of Health- Related Quality Of Life For Patients With Renal Failure. Current Medical Research And Opinion, Vol.11, No.21, (1777–83).
• Levey, A., Atkins, R., & Coresh, J. (2007). Chronic kidney disease as a global public health problem: approaches and initiatives–a position statement from Kidney Disease Improving Global Outcomes. International http://www.nature.com/ki/journal/v72/n3/abs/5002343a.html, (11.06.2013). Society of Nephrology (C. 83).
• Mallick, N. P. (1995). What Do We Learn From The European Registry: What Will Be The Underlying Problems In The Year 2000? Nephrology, Dialysis, Transplantation  : Official Publication Of The European Dialysis And Transplant Association, European Renal Association, 10 Suppl 7, (2–6).
• Matas, A. J.,Schnitzler, M. (2004). Payment for Living Donor (Vendor) Kidneys: A Cost-Effectiveness Analysis, American Journal of Transplantation, Vol.2, No.4, (216–221).
• Mauskopf, J. (1998). Prevalence-Based Economic Evaluation. Value İn Health  : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research, Vol.4, No.1, (251–9).
• Mauskopf, J. A., Sullivan, S. D., Annemans, L., Caro, J., Mullins, C. D., Nuijten, M., … Trueman, P. (2007). Principles Of Good Practice For Budget Impact Analysis: Report Of The ISPOR Task Force On Good Research Practices--Budget Impact Analysis. Value In Health  : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research, Vol.5, No.10, (336–47).
• Nugent, R. A., Fathima, S. F., Feigl, A. B., & Chyung, D. (2011). The Burden Of Chronic Kidney Disease On Developing Nations: A 21st Century Challenge In Global Health. Nephron Clinical Practice, Vol.3, No.118, (c269–c277).
• OECD. (2014). Health-Statistics. http://www.oecd.org/els/health-systems/health-statistics.htm (01.2.2014).
• Özgen, H.,Tatar, M. (2007). Sağlık Sektöründe Bir Verimlilik Değerlendirme Tekniği Olarak Maliyet-Etkililik Analizi ve Türkiye’de Durum. Hacettepe Sağlık İdaresi Dergisi, Cilt.2,Sayı.10, (109–137).
• Perico, N., Bravo, R. F., De Leon, F. R., & Remuzzi, G. (2009). Screening For Chronic Kidney Disease İn Emerging Countries: Feasibility And Hurdles, Nephrology Dialysis Transplantation, 24(February), (1355–1358).
• Polsky, D., Weinfurt, K. P., Kaplan, B., Kim, J., Fastenau, J., & Schulman, K. A. (2001). An Economic And Quality-Of-Life Assessment Of Basiliximab Vs Antithymocyte Globulin İmmunoprophylaxis İn Renal Transplantation. Nephrology, Dialysis, Transplantation, Vol.5, No.16, (1028–33).
• Roberts, S. D., Maxwell, D. R., & Gross, T. L. (1980). Cost-Effective Care Of End-Stage Renal Disease: A Billion Dollar Question, Annals Of İnternal Medicine, No.92(2_Part_1), (243–248).
• Rushby, J.F., Cairns, J. (2005). The Structure Of Economic Evaluation (1) And Measuring And Valuing Consequences (2). Içinde J. Rushby, J.F., Cairns (Ed.), Economic Evaluation (4. baskı). Open University Press.
• Russell, L. B., Gold, M. R., Siegel, J. E., Daniels, N., Weinstein, M. C. (1996), The Role of Cost-Effectiveness Analysis in Health and Medicine, JAMA: The Journal of The American Medical Association, Vol.14, No.276, (1172-1177)
• Sağıroğlu, T., Yıldırım, M., Meydan, B., & Çobanoğlu, M. (2009). Böbrek Transplantasyonu Hastalarının Retrospektif Analizi, Dicle Tıp Dergisi, Cilt.3, No.36, (75–79).
• Sahin, S., Toprak, S., Nal, E. (2012). QALY: Quality Adjusted Life Year, Medicine Science, Vol.4, No.1, (232- 43).
• Schaubel, D. E., Morrison, H. I., Desmeules, M., Parsons, D., Fenton, S. S. (1998), End-Stage Renal Disease
• Projections For Canada To 2005 Using Poisson and Markov Models, International Journal of
• Epidemiology, Vol.2, No.27, (274-281).
• Schweitzer, E. J., Perencevich, E. N., Philosophe, B., & Bartlett, S. T. (2007). Estimated Benefits Of Transplantation Of Kidneys From Donors At Increased Risk For HIV Or Hepatitis C Infection. American Journal Of Transplantation, Vol.6, No.7, (1515–1525).
• Sennfält, K., Magnusson, M., & Carlsson, P. (2002). Comparison Of Hemodialysis And Peritoneal Dialysis--A Cost-Utility Analysis. Peritoneal Dialysis International  : Journal Of The International Society For Peritoneal Dialysis, Vol.1, No.22, (39–47).
• Sullivan, S. D., Mauskopf, J. a, Augustovski, F., Jaime Caro, J., Lee, K. M., Minchin, M., … Shau, W.-Y. (2014). Budget Impact Analysis-Principles Of Good Practice: Report Of The ISPOR 2012 Budget Impact Analysis Good Practice II Task Force, Value in Health  : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research, Vol.1, No.17, (5–14).
• Süleymanlar , G. , Al tıparmak , M
• R., & Nurhan, S. (2014). Tü rkı̇ ye ’de Nefr olo
• ji, Diyaliz ve Transplantasyon
• (Registry 2013), T.C. Sağlık Bakanlığı ve Türk Nefroloji Derneği Ortak Raporu. Ankara.
• Süleymanlar, G., Serdengeçti, K., & Ekrem, E. (2005). Türkiye’de Son Dönem Böbrek Yetmezliğinin Epidemiyolojisi, Türkiye Klinikleri Dahili Tıp Bilimleri Dergisi, Cilt.1, Sayı.21, (1–8).
• Süleymanlar, G., Utaş, C., Arinsoy, T., Ateş, K., Altun, B., Altiparmak, M. R., … Serdengeçti, K. (2011). A Population-Based Survey Of Chronic Renal Disease In Turkey--The CREDIT Study. Nephrology, Dialysis, Transplantation  : Official Publication Of The European Dialysis And Transplant Association - European Renal Association, Vol.6, No.26, (1862–71).
• USRDS. (2012). Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Annual Data Report. http://www.usrds.org/adr.aspx. (2.2.2013).
• Utaş, C. (2007). Diyaliz Uygulamalarında Maliyet Analizi, Türk Nefroloji Diyaliz ve Transplantasyon Dergisi, 16(Ek-2), (73–76).
• Vanholder, R., Wanner, C., Caskey, F., Couchoud, C., Fouque, D., Groothoff, J., … Al., E. (2014). ERA-EDTA Registry: Annual Report 2012. The Netherlands. Tarihinde adresinden erişildi www.era-edta-reg.org
• Villa, G., Fernández-Ortiz, L., Cuervo, J., Rebollo, P., Selgas, R., González, T., Arrieta, J. (2012). Cost- Effectiveness Analysis Of The Spanish Renal Replacement Therapy Program. Peritoneal Dialysis İnternational  : Journal Of The International Society For Peritoneal Dialysis, Vol., No.32, (192–9).
• Villa, G., Sánchez-Álvarez, E., Cuervo, J., Fernández-Ortiz, L., Rebollo, P., Ortega, F. (2012). Cost- Effectiveness Analysis Of Timely Dialysis Referral After Renal Transplant Failure In Spain. BMC Health Services Research, Vol.1, No.12, (257) WHO. (2013), (01.07.2013). Thresholds,
• http://www.who.int/choice/costs/CER_thresholds/en/
• Wolfe, R. A., Ashby, V. B., Milford, E. L., Ojo, A. O., Ettenger, R. E., Agodoa, L. Y., … Port, F. K. (1999). Comparison Of Mortality İn All Patients On Dialysis, Patients On Dialysis Awaiting Transplantation, And Recipients Of A First Cadaveric Transplant, The New England Journal Of Medicine, Vol.23, No.341, (1725–30).
• Wu, A. W., Fink, N. E., Marsh-Manzi, J. V. R., Meyer, K. B., Finkelstein, F. O., Chapman, M. M., & Powe, N. R. (2004). Changes In Quality Of Life During Hemodialysis And Peritoneal Dialysis Treatment: Generic And Disease Specific Measures, Journal of the American Society of Nephrology  : JASN, Vol.3, No.15, (743–53).
• Xin, S. U. N. (2007). Markov Modelling In Healthcare Economic Evaluations, Chin J Evid-based Med, Vol.10, No.7, (750-756).
• Yiğit, V. (2013). Sağlık Hizmetlerinde Ekonomik Değerlendirme: Türkiye’de Diyaliz ve Böbrek Transplantasyonu Tedavi Yöntemlerinin Maliyet Etkililik Analizi. Isparta: Süleyman Demirel Üniversitesi, Sosyal Bilimler Enstitüsü Sağlık Kurumları Yönetimi Anabilim Dalı, Doktora Tezi, Isparta.
• Çelik Y. (2011). Sağlık Ekonomisi. Ankara: Siyasal Kitabevi.
• Zhang, Q.-L.,& Rothenbacher, D. (2008). Prevalence Of Chronic Kidney Disease In Population-Based Studies: Systematic Review, BMC Public Health, Vol.1, No.8, (117).